Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8481526 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Jan, 2031
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8937062 | BAUSCH AND LOMB | Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria |
Nov, 2029
(6 years from now) | |
US8604020 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Mar, 2030
(7 years from now) | |
US8415342 | BAUSCH AND LOMB | Besifloxacin ophthalmic composition for the treatment or control of infection |
Nov, 2030
(7 years from now) |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2009
Treatment: Method of treating ocular bacterial infections
Dosage: SUSPENSION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8129431 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Sep, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8927606 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(11 months from now) | |
US9561277 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(11 months from now) | |
US8871813 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(11 months from now) | |
US9144609 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(11 months from now) | |
US8669290 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(11 months from now) | |
US8754131 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(11 months from now) | |
US10085958 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2032
(9 years from now) | |
US9517220 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2033
(10 years from now) |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: Method of treating ocular inflammation; Method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8058467 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 10 months from now) | |
US7910767 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 10 months from now) | |
US7273946 | BAUSCH AND LOMB | Prostaglandin derivatives |
Oct, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7629345 | BAUSCH AND LOMB | Prostaglandin derivatives |
Jan, 2025
(1 year, 10 months from now) |
Drugs and Companies using LATANOPROSTENE BUNOD ingredient
Market Authorisation Date: 02 November, 2017
Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic